Altre lingue TransCode Therapeutics, Inc.

Azioni

RNAZ

US89357L3033

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:01 03/05/2024			Variaz. 5gg	Var. 1 gen.
0,82 ^USD	+15,98%		+49,12%	-87,56%

15/04	TransCode Therapeutics, Inc. annuncia l'autorizzazione dell'Fda a iniziare la sperimentazione clinica di Fase 1/2 con il farmaco Ttx-Mc138 in pazienti con tumori solidi avanzati	CI
01/04	TransCode Therapeutics, Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

TransCode Therapeutics : Shareholder Meeting - Form 8-K	23/04
Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.	22/04
Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.	22/04
Certain Common Stock of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.	22/04
TransCode Therapeutics Cleared by FDA for Phase 1/2 Trial of TTX-MC138 for Advanced Solid Tumors	15/04
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors	15/04
TransCode Therapeutics, Inc. Announces Fda Clearance to Initiate Phase 1/2 Clinical Trial Withttx-Mc138 in Patients with Advanced Solid Tumors	15/04
TransCode Therapeutics Reports 2023 Results; Provides Business Update	03/04
TransCode Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer	28/03
TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer	28/03
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment	11/03
TransCode Therapeutics, Inc. and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment	11/03
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic	20/02
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode?s RIG-I Agonist Immunotherapeutic	20/02
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market	31/01
TransCode Therapeutics, Debiopharm Collaborate to Develop Nucleic Acid Therapies for Cancer	29/01
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer	29/01
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer	29/01
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering	22/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue TransCode Therapeutics, Inc.

Azioni

RNAZ

US89357L3033

Altre lingue

Filtri